Kinnate Biopharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Kinnate Biopharma Inc (KNTE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Kinnate Biopharma Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Kinnate Biopharma Inc | - | - | - | Yes |
| Competitors combined (177) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
KNTE Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Erasca Inc | 282.9% | Outperformed |
| 3 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 4 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 5 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Kinnate Biopharma Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Kinnate Biopharma Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Kinnate Biopharma Inc | 123.42 | - |
| Astrazeneca Plc | 245,077.80 | 58,739.00 |
| Amgen Inc | 219,253.76 | 38,095.00 |
| Vertex Pharmaceuticals Inc | 128,807.10 | 12,587.20 |
| Bristol myers Squibb Company | 125,235.20 | 49,186.00 |
| Regeneron Pharmaceuticals Inc | 77,931.20 | 15,534.70 |
| SUBTOTAL | 1,131,213.28 | 219,227.22 |
Sign in to see all competitors of Kinnate Biopharma Inc .
Sources: Kinnate Biopharma Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Kinnate Biopharma Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Kinnate Biopharma Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Springworks Therapeutics Inc | Named by the company | 85% |
| Nuvalent Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Kinnate Biopharma Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Kinnate Biopharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
| Viatris Inc | Developed Markets 57.61 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Kinnate Biopharma Inc .
Kinnate Biopharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Kinnate Biopharma Inc | 123 | - | -1,137,869 |
| Astrazeneca Plc | 245,078 | 706,847 | 123,141 |
| Amgen Inc | 219,254 | 2,930,385 | 672,538 |
| Vertex Pharmaceuticals Inc | 128,807 | 31,079,506 | 10,877,037 |
| Bristol myers Squibb Company | 125,235 | 1,513,415 | 285,354 |
| Regeneron Pharmaceuticals Inc | 77,931 | 1,008,092 | 280,902 |
| PEERS TOTAL | 1,131,090 | 953,431 | 120,645 |
Sign in to see all peers for Kinnate Biopharma Inc .
Kinnate Biopharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| United Therapeutics Corporation | UNITED STATES 95.23 % |
| Hutchmed china Limited | CN 74.28 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Kinnate Biopharma Inc .
Kinnate Biopharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 0.4x | 4.5x | -4.1x |
| Return on Equity | -62.31 % | industry aggregate | -73.77 % |
| Return on Invested Capital | -32.06 % | -2.89 % (avg) | -29.17 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Kinnate Biopharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 73.8 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (50.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-38.6% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Kinnate Biopharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Kinnate Biopharma Inc | 3.51 | 11.71 | 0.00 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
Sign in to see all peers for Kinnate Biopharma Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Kinnate Biopharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Kinnate Biopharma Inc | Q3 2023 | - | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| PEERS TOTAL | +9.0 % | +77.0 % |
Sign in to see all peers for Kinnate Biopharma Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Kinnate Biopharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Kinnate Biopharma Inc | Q3 2023 | - | - |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
Sign in to see all peers for Kinnate Biopharma Inc .
Kinnate Biopharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Kinnate Biopharma Inc | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
Sign in to see all peers for Kinnate Biopharma Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Kinnate Biopharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Kinnate Biopharma Inc | - | - |
| Astrazeneca Plc | 23.97 | 4.17 |
| Amgen Inc | 25.03 | 5.76 |
| Vertex Pharmaceuticals Inc | 29.43 | 10.23 |
| Bristol myers Squibb Company | 13.46 | 2.55 |
| Regeneron Pharmaceuticals Inc | 18.21 | 5.02 |
| PEERS AVERAGE | 40.94 | 5.16 |
Sign in to see all peers for Kinnate Biopharma Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.